About the Company
Harrow Health, formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company (Nasdaq: HROW) based in Nashville, TN. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing. In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its Chief Innovation Officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ETON News
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call Transcript March 14, 2024 Eton Pharmaceuticals, Inc. isn't one ...
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.04 per share a year ago.
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing ...
Eton Pharma Buys U.S. Rights To PKU GOLIKE From Relief Therapeutics
(RTTNews) - Eton Pharmaceuticals Inc (ETON) said that it has acquired U.S. rights to PKU GOLIKE from Relief Therapeutics Holding SA. PKU is a rare inherited disorder caused by a defect in the ...
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing ...
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call Transcript
Eton Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Eton ...
Eton Pharmaceuticals Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Q4 2023 Eton Pharmaceuticals Inc Earnings Call
David Krempa; Chief Business Officer; Eton Pharmaceuticals, Inc. Sean Brynjelsen; CEO; Eton Pharmaceuticals, Inc. James Gruber; CFO; Eton Pharmaceuticals, Inc ...
Loading the latest forecasts...